• In the first quarter of 2022, AREV acquired Wright & Well Essentials Inc., a firm with an extensive hemp and cannabis line of branded products currently sold in Oregon and expanding markets.
• The company’s online sales and marketing platform, Medicine Merchant, is in the final stages of development; the platform has the potential to revolutionize consumer access to therapeutic interventions and personalized medicine via partnerships with telemedicine providers.
• A recent peer-reviewed study by a member of AREV’s scientific advisory board (“SAB”) has demonstrated the potential utility of specific cannabinoids against all variants of COVID-19.
• Further additions to AREV’s SAB in the second half of 2022 are expected to provide additional opportunities for establishing collaborations with academic institutions and orchestrating the acquisition of promising IP.
• AREV is developing a Ready-to-Use Therapeutic Food (“RUTF”) utilizing proprietary extraction techniques intended to treat inanition which results from the metabolic effects of starvation.
• Regulatory submission of AREV’s RESTORE enteral formula in the United States and Canadian markets is scheduled for the second half of 2022, with initial clinical studies expected to commence in Q4 2022.
• Verified Market Research valued the worldwide RUTF market at $363.72 million in 2019 and projected growth to $807.89 million by 2027, expanding at a CAGR of 10.5% for the forecast period.
• The global enteral feeding formulas market was valued at $5.9 billion in 2020 and is expected to expand at a CAGR of 5.9% through 2028, according to Grandview Research.

AREV Life Sciences Global (CSE: AREV) (OTC: AREVF) is a fully integrated, publicly traded, early-stage life science enterprise dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful collaborations in the life science industry. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system.

AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board (“SAB”), experienced staff, and executive leadership to drive its product pipeline. AREV’s strategy is to generate revenue from selling its branded products via…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to AREVF are available in the company’s newsroom at https://ibn.fm/AREVF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.